MX2022009477A - Metodos para el tratamiento de sintomas neurologicos asociados con las enfermedades de almacenamiento lisosomico. - Google Patents
Metodos para el tratamiento de sintomas neurologicos asociados con las enfermedades de almacenamiento lisosomico.Info
- Publication number
- MX2022009477A MX2022009477A MX2022009477A MX2022009477A MX2022009477A MX 2022009477 A MX2022009477 A MX 2022009477A MX 2022009477 A MX2022009477 A MX 2022009477A MX 2022009477 A MX2022009477 A MX 2022009477A MX 2022009477 A MX2022009477 A MX 2022009477A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lysosomal storage
- storage diseases
- neurological symptoms
- symptoms associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969568P | 2020-02-03 | 2020-02-03 | |
| US202063029154P | 2020-05-22 | 2020-05-22 | |
| US202063072714P | 2020-08-31 | 2020-08-31 | |
| PCT/IB2021/050879 WO2021156769A1 (en) | 2020-02-03 | 2021-02-03 | Methods for treating neurological symptoms associated with lysosomal storage diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009477A true MX2022009477A (es) | 2022-08-22 |
Family
ID=74592326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009477A MX2022009477A (es) | 2020-02-03 | 2021-02-03 | Metodos para el tratamiento de sintomas neurologicos asociados con las enfermedades de almacenamiento lisosomico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12083115B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4100009A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023512366A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220136887A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115427038A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021215396B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022014553A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3166777A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295255A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009477A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202142236A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021156769A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| PT3920912T (pt) | 2019-02-04 | 2025-09-09 | Genzyme Corp | Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs) |
| IL295255A (en) | 2020-02-03 | 2022-10-01 | Genzyme Corp | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| IL300090A (en) | 2020-07-24 | 2023-03-01 | Genzyme Corp | Pharmaceutical preparations containing VENGLUSTAT |
| US20250107713A1 (en) * | 2023-09-29 | 2025-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and Methods for Confirming Iboga Alkaloid Treatment |
| WO2025219952A1 (en) * | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| TW202604489A (zh) * | 2024-04-19 | 2026-02-01 | 美商健臻公司 | 用於降低患有神經節苷脂儲積症的患者中的疾病相關生物標誌物水準之方法 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB725228A (en) | 1952-06-19 | 1955-03-02 | Roche Products Ltd | Substituted carbamic acid esters and process for the manufacture thereof |
| BE640616A (cg-RX-API-DMAC7.html) | 1962-12-19 | |||
| NL130759C (cg-RX-API-DMAC7.html) | 1965-10-07 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4593034A (en) | 1984-04-06 | 1986-06-03 | A. H. Robins Company, Inc. | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides |
| IE63474B1 (en) | 1987-12-24 | 1995-04-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| ATE85217T1 (de) | 1988-08-04 | 1993-02-15 | Synthelabo | Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.>oct-3-yl)benzamide und thiobenzamide. |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| IT1228293B (it) | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
| DK443489D0 (da) | 1989-09-08 | 1989-09-08 | Ferrosan As | Substituerede urinstofforbindelser, deres fremstilling og anvendelse |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| GB9106571D0 (en) | 1991-03-27 | 1991-05-15 | Erba Carlo Spa | Derivatives of substituted imidazol-2-one and process for their preparation |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| AU685225B2 (en) | 1994-02-10 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| JPH08198751A (ja) | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
| JP2000500139A (ja) | 1995-11-08 | 2000-01-11 | アメリカン・ホーム・プロダクツ・コーポレイション | 1−アザビシクロヘプタン誘導体およびそれらの医薬用途 |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| EE9900034A (et) | 1996-07-29 | 1999-08-16 | Pharmacia & Upjohn Ab | Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine |
| EP1027069B1 (en) | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
| CN1332726A (zh) | 1998-11-02 | 2002-01-23 | 卫福有限公司 | 吡咯烷化合物及其药物用途 |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| PL357099A1 (en) | 2000-02-07 | 2004-07-12 | Abbott Gmbh & Co.Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| AU2001266100B9 (en) | 2000-06-27 | 2005-10-06 | Laboratorios S.A.L.V.A.T., S.A. | Carbamates derived from arylalkylamines |
| US6492386B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| WO2002015662A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| EP1345937B1 (en) | 2000-12-22 | 2005-09-28 | Almirall Prodesfarma AG | Quinuclidine carbamate derivatives and their use as m3 antagonists |
| DE60216830T2 (de) | 2001-02-06 | 2007-06-14 | Pfizer Products Inc., Groton | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen |
| JP2003267977A (ja) | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
| DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2393331T3 (es) | 2002-07-17 | 2012-12-20 | Actelion Pharmaceuticals Ltd. | Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa |
| AU2003248122A1 (en) | 2002-07-25 | 2004-02-16 | Kotobuki Pharmaceutical Co., Ltd. | Sodium channel inhibitor |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| ATE378048T1 (de) | 2002-12-06 | 2007-11-15 | The Feinstein Inst Medical Res | Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| TW200529860A (en) | 2003-12-22 | 2005-09-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JP2007186422A (ja) | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
| JP2008504282A (ja) | 2004-06-23 | 2008-02-14 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | コリンレセプターの薬理活性により腸閉塞を処置する方法 |
| BRPI0517701A8 (pt) | 2004-11-10 | 2018-01-23 | Genzyme Corp | métodos de tratamento de diabetes mellitus |
| EP1891048A1 (en) | 2005-06-11 | 2008-02-27 | Vernalis (R&D) Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| CN101312968A (zh) | 2005-09-23 | 2008-11-26 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途 |
| SG131819A1 (en) | 2005-11-07 | 2007-05-28 | Chikka Pte Ltd | Buddy-based cross-carrier messaging system |
| JP2009523845A (ja) | 2006-01-23 | 2009-06-25 | クリスタルゲノミクス インコーポレーテッド | たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物 |
| US20090318491A1 (en) | 2006-01-27 | 2009-12-24 | Yale Univeristy | Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders |
| WO2008096870A1 (ja) | 2007-02-09 | 2008-08-14 | Astellas Pharma Inc. | アザ架橋環化合物 |
| EP2142197A4 (en) | 2007-03-30 | 2010-11-10 | Amicus Therapeutics Inc | METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES |
| CA2707360A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes |
| EP2211856A4 (en) | 2007-11-29 | 2011-02-09 | Hospital For Sick Children | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER |
| JP2011529500A (ja) | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| EP2154136A1 (en) | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| WO2010091104A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| WO2010091164A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| CN102438988B (zh) | 2009-04-21 | 2015-06-24 | 内尔维阿诺医学科学有限公司 | 作为hsp90抑制剂的间苯二酚衍生物 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2456438A2 (en) | 2009-07-23 | 2012-05-30 | Novartis AG | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives |
| CA2773133A1 (en) | 2009-08-28 | 2011-03-03 | Edward H. Schuchman | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| US20110183938A1 (en) | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
| AU2011327113B9 (en) | 2010-11-12 | 2015-07-30 | Shionogi & Co., Ltd. | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same |
| LT2685986T (lt) | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
| US20140228575A1 (en) | 2011-06-22 | 2014-08-14 | Isochem | Process for the Preparation of Solifenacin and Salts Thereof |
| AU2012272815B2 (en) | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| PL4066849T3 (pl) | 2012-09-11 | 2025-06-16 | Hospira Australia Pty Ltd | Preparaty daptomycyny i ich zastosowania |
| JO3713B1 (ar) | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| TW201900625A (zh) | 2013-03-15 | 2019-01-01 | 美商健臻公司 | 製備葡糖基神經醯胺合成酶抑制劑之方法 |
| EP3079695B1 (en) | 2013-12-11 | 2021-03-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| EP3412296B1 (en) * | 2016-02-05 | 2025-11-12 | Kyungpook National University Industry-Academic Cooperation Foundation | Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease |
| JP7585561B2 (ja) * | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| PT3920912T (pt) | 2019-02-04 | 2025-09-09 | Genzyme Corp | Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs) |
| SG11202107844UA (en) | 2019-02-04 | 2021-08-30 | Genzyme Corp | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
| IL295255A (en) | 2020-02-03 | 2022-10-01 | Genzyme Corp | Methods for treating neurological symptoms associated with lysosomal storage diseases |
-
2021
- 2021-02-03 IL IL295255A patent/IL295255A/en unknown
- 2021-02-03 CN CN202180025025.5A patent/CN115427038A/zh active Pending
- 2021-02-03 KR KR1020217038776A patent/KR20220136887A/ko active Pending
- 2021-02-03 TW TW110104027A patent/TW202142236A/zh unknown
- 2021-02-03 WO PCT/IB2021/050879 patent/WO2021156769A1/en not_active Ceased
- 2021-02-03 MX MX2022009477A patent/MX2022009477A/es unknown
- 2021-02-03 US US17/166,863 patent/US12083115B2/en active Active
- 2021-02-03 CA CA3166777A patent/CA3166777A1/en active Pending
- 2021-02-03 AU AU2021215396A patent/AU2021215396B2/en active Active
- 2021-02-03 BR BR112022014553A patent/BR112022014553A2/pt unknown
- 2021-02-03 JP JP2021564953A patent/JP2023512366A/ja active Pending
- 2021-02-03 EP EP21704944.4A patent/EP4100009A1/en active Pending
-
2025
- 2025-09-17 JP JP2025153760A patent/JP2026001009A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026001009A (ja) | 2026-01-06 |
| EP4100009A1 (en) | 2022-12-14 |
| IL295255A (en) | 2022-10-01 |
| AU2021215396A1 (en) | 2022-09-29 |
| US12083115B2 (en) | 2024-09-10 |
| CA3166777A1 (en) | 2021-08-12 |
| CN115427038A (zh) | 2022-12-02 |
| BR112022014553A2 (pt) | 2022-09-20 |
| KR20220136887A (ko) | 2022-10-11 |
| WO2021156769A1 (en) | 2021-08-12 |
| JP2023512366A (ja) | 2023-03-27 |
| TW202142236A (zh) | 2021-11-16 |
| US20210251982A1 (en) | 2021-08-19 |
| AU2021215396B2 (en) | 2026-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014553A2 (pt) | Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic | |
| Stefánsson et al. | Retinal oximetry: metabolic imaging for diseases of the retina and brain | |
| Wen et al. | The perineuronal ‘safety’net? Perineuronal net abnormalities in neurological disorders | |
| Franklin et al. | Astrocytes and microglia in neurodegenerative diseases: Lessons from human in vitro models | |
| Dorey et al. | The clinical features of albinism and their correlation with visual evoked potentials | |
| Bazzichi et al. | One year in review 2016: fibromyalgia | |
| WO2017062456A3 (en) | Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof | |
| MY168084A (en) | Methods for treating and/or reversing neurodegenerative diseases and/or disorders | |
| Bliwise et al. | Phasic muscle activity in sleep and clinical features of Parkinson disease | |
| WO2017156279A3 (en) | Methods and systems for assessing infertility and ovulatory function disorders | |
| Kasai et al. | Early sinusoidal heart rate patterns and heart rate variability to assess hypoxia–ischaemia in near‐term fetal sheep | |
| Zalewski et al. | Cardiovascular and Thermal Response to Dry‐Sauna Exposure in Healthy Subjects | |
| Jhunjhunwala et al. | Alterations in cortical excitability and central motor conduction time in spinocerebellar ataxias 1, 2 and 3: a comparative study | |
| MX2025005880A (es) | Metodos de tratamiento que usan un nivel de tomografia de emision de positrones (pet) de tau | |
| Martins-Macedo et al. | Adult brain cytogenesis in the context of mood disorders: From neurogenesis to the emergent role of gliogenesis | |
| Rodriguez et al. | Cluster analysis and correlations between cognitive domains: cognitive performance in a Czech sample of first episodes schizophrenia spectrum disorders-Preliminary results | |
| Rankin et al. | Corneal sensitivity in healthy, immature, and adult alpacas | |
| Blank et al. | The development and physiological and pathophysiological functions of resident macrophages and glial cells | |
| Cornes | Chronic fatigue syndrome: a patient’s perspective | |
| Hamblen et al. | Screening and assessment. | |
| Iranzo et al. | Rapid eye movement sleep behaviour | |
| Coon et al. | Pattern and evolution of sudomotor dysfunction in Multiple System Atrophy | |
| Eliasson | Pneumatic compression devices for treatment of restless legs syndrome | |
| Stamboulis et al. | Cardiac vagal tests and vagus nerve stimulation in epilepsy | |
| Lesenskyj et al. | (393) Neuropathic pain reduction with scrambler therapy treatment |